PriceTargets.com logo

NASDAQ:IMAC - IMAC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.63
  • Forecasted Upside: 103.65 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.78 As of 01/25/2021 01:00 AM ET
▲ +0.04 (2.30%)
1 month | 3 months | 12 months
Get New IMAC Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMAC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.63
▲ +103.65% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for IMAC in the last 3 months. The average price target is $3.63, with a high forecast of $4.50 and a low forecast of $2.75. The average price target represents a 103.65% upside from the last price of $1.78.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in IMAC. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2020Alliance Global PartnersInitiated CoverageBuy$2.75Low
i
4/15/2020Ascendiant Capital MarketsInitiated CoverageBuy$4.50Medium
i
1/14/2020Dawson JamesReiterated RatingBuy ➝ NeutralLow
i
Rating by J. Kolbert at Dawson James
(Data available from 1/25/2016 forward)
IMAC logo
IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. As of March 26, 2020, the company owned or managed 14 outpatient clinics in Kentucky, Missouri, Tennessee, and Illinois. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.
Read More

Today's Range

Now: $1.78
$1.69
$1.80

50 Day Range

MA: $1.42
$0.99
$1.95

52 Week Range

Now: $1.78
$0.42
$4.95

Volume

135,162 shs

Average Volume

555,206 shs

Market Capitalization

$21.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of IMAC?

The following Wall Street research analysts have issued research reports on IMAC in the last twelve months: Alliance Global Partners, Ascendiant Capital Markets, and Zacks Investment Research.

What is the current price target for IMAC?

2 Wall Street analysts have set twelve-month price targets for IMAC in the last year. Their average twelve-month price target is $3.63, suggesting a possible upside of 103.7%. Ascendiant Capital Markets has the highest price target set, predicting IMAC will reach $4.50 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.75 for IMAC in the next year.

What is the current consensus analyst rating for IMAC?

IMAC currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMAC will outperform the market and that investors should add to their positions of IMAC.

What other companies compete with IMAC?

Other companies that are similar to IMAC include Acadia Healthcare, BioTelemetry, Hanger, Aesthetic Medical International Holdings Group, BioCorRx, AAC and Ceres Ventures.

How do I contact IMAC's investor relations team?

IMAC's physical mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company's listed phone number is 844-266-4622 and its investor relations email address is [email protected] The official website for IMAC is www.imacregeneration.com.